常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.08/-0.99
|
|
企业价值
39.06M
|
| 资产负债 |
|
每股账面净值
0.95
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
14.00K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/19 01:43 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others. |

1.5 
